ICPT
$128.82
Intercept Pharmaceut
$.04
.03%
ICPT
Earnings Whisper ®
N/A
2nd Quarter June 2017
Consensus:  ($3.62)
Revenue:  $26.99 Mil
Monday
Jul 31
7:05 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ICPT reports earnings?
Beat
Meet
Miss

Where is ICPT's stock price going from here?
Up
Flat
Down
Stock chart of ICPT
Analysts
Summary of analysts' recommendations for ICPT
Score
Grade
Pivots
Resistance
$134.58
$132.79
$130.80

$129.01

Support
$127.02
$125.23
$123.24
Tweet
Growth
Description
Intercept Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease. The company's lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC). Intercept Pharmaceuticals Inc. is headquartered in New York.
Peers
Regeneron PharmaceuticalsVertex PharmaceuticalsJohnson & JohnsonCelgeneEli LillyZoetisBioMarin PharmaceuticalEndo International plcPfizerBristol-Myers Squibb